Back to Search
Start Over
High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab
- Source :
- Modern Rheumatology. 28:119-125
- Publication Year :
- 2017
- Publisher :
- Oxford University Press (OUP), 2017.
-
Abstract
- This study aimed to determine whether serum matrix metalloproteinase-3 (MMP-3) levels can predict remission in rheumatoid arthritis (RA) patients treated with adalimumab (ADA).Subjects were 114 RA patients continuously treated with ADA for 52 weeks. Predictive factors at baseline and 4 weeks after initiation of ADA therapy for the achievement of remission (28-point count Disease Activity Score-CRP (DAS28-CRP) 2.3) at 52 weeks were evaluated by multivariate logistic regression analysis.DAS28-CRP at 4 weeks (odds ratio (OR) 0.614, 95% confidence interval (CI) 0.382-0.988) and improvement in serum MMP-3 levels at 4 weeks (OR 1.057, 95% CI 1.002-1.032) were independent predictors of remission at 52 weeks. The best cut-off level of DAS28-CRP and improvement in serum MMP-3 levels at 4 weeks for predicting remission at 52 weeks was 3.73 (sensitivity: 90%, specificity: 50%, area under the receiver operating characteristic curve (AUC): 62%) and 39.93% (sensitivity: 47%, specificity: 83%, AUC: 64%), respectively.Our findings suggest that a high rate of improvement in serum MMP-3 levels at 4 weeks after initiation of ADA therapy can predict remission at 52 weeks in RA patients.
- Subjects :
- Adult
Male
musculoskeletal diseases
0301 basic medicine
Matrix Metalloproteinase 3
medicine.medical_specialty
Time Factors
Treatment outcome
Gastroenterology
Arthritis, Rheumatoid
03 medical and health sciences
Remission induction
0302 clinical medicine
Rheumatology
Internal medicine
Adalimumab
Humans
Medicine
skin and connective tissue diseases
Aged
030203 arthritis & rheumatology
High rate
biology
business.industry
Remission Induction
C-reactive protein
Middle Aged
medicine.disease
C-Reactive Protein
Treatment Outcome
030104 developmental biology
Antirheumatic Agents
Rheumatoid arthritis
Immunology
biology.protein
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 14397609 and 14397595
- Volume :
- 28
- Database :
- OpenAIRE
- Journal :
- Modern Rheumatology
- Accession number :
- edsair.doi.dedup.....d6594122a0a081e74ac4dde3c8623e04